Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.33 |
| ▸ | EEF2K | O00418 | 2/20 | 0.33 |
| ▸ | EEF2 | P13639 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | PLK4 | O00444 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ITK | Q08881 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL294563 | 0.98 | — | — | |
| SCHEMBL28238038 | 0.98 | CTDSP1 (0.36) | CA1CA2CTDSP1POLBAPOBEC3A | |
| Water SCHEMBL15361632 | 0.95 | CTDSP1 (0.35) | CA1CA2CTDSP1POLBAPOBEC3A | |
| Iodide SCHEMBL2037552 | 0.95 | CTDSP1 (0.39) | CA1CA2CTDSP1POLBAPOBEC3A | |
| Hydrochloric Acid SCHEMBL385497 | 0.95 | CTDSP1 (0.35) | CA1CA2CTDSP1POLBAPOBEC3A | |
| Fluoride Ion SCHEMBL1900591 | 0.95 | CTDSP1 (0.35) | CA1CA2CTDSP1POLBAPOBEC3A | |
| Bromide SCHEMBL1331600 | 0.92 | CA1 (0.35) | CA1CA2CTDSP1POLBAPOBEC3A | |
| SCHEMBL6649711 | 0.90 | CA1 (0.33) | CA1CA2CTDSP1POLBAPOBEC3A | |
| SCHEMBL4245376 | 0.90 | HDAC8 (0.34) | CA1CA2CTDSP1POLBAPOBEC3A | |
| SCHEMBL384801 | 0.90 | CA1 (0.33) | CA1CA2CTDSP1POLBAPOBEC3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617892-B2 | Application of the ring-opening of uretdiones at low temperature and ambient atmosphere | BASF SE (DE) | 2026-05-05 | — | — | US | claimed |
| US-12509547-B2 | Synthesis of linear polyoxazolidinones using uretdiones as diisocyanate component | BASF SE (DE) | 2025-12-30 | — | — | US | claimed |
| CN-118324779-A | Preparation method of cefotaxime acid | 广西科伦制药有限公司 | 2024-07-12 | — | — | CN | claimed |
| US-20230348657-A1 | SYNTHESIS OF LINEAR POLYOXAZOLIDINONES USING URETDIONES AS DIISOCYANATE COMPONENT | BASF SE (DE) | 2023-11-02 | — | — | US | claimed |
| US-20230323013-A1 | APPLICATION OF THE RING-OPENING OF URETDIONES AT LOW TEMPERATURE AND AMBIENT ATMOSPHERE | BASF SE (DE) | 2023-10-12 | — | — | US | claimed |
| EP-4185627-A1 | APPLICATION OF THE RING-OPENING OF URETDIONES AT LOW TEMPERATURE AND AMBIENT ATMOSPHERE | BASF SE (DE) | 2023-05-31 | — | — | EP | claimed |
| EP-4185626-A1 | SYNTHESIS OF LINEAR POLYOXAZOLIDINONES USING URETDIONES AS DIISOCYANATE COMPONENT | BASF SE (DE) | 2023-05-31 | — | — | EP | claimed |
| CN-116134063-A | Application of ring opening of uretdione at low temperature and normal pressure | 巴斯夫欧洲公司 | 2023-05-16 | — | — | CN | claimed |
| EP-3824012-B1 | BULK POLYMERISATION OF POLYOXAZOLIDONE | BASF SE (DE) | 2022-09-07 | — | — | EP | claimed |
| EP-3964536-A1 | POLYOXAZOLIDINONE INTERMEDIATE CONTAINING AN ANTIOXIDANT | BASF SE (DE) | 2022-03-09 | — | — | EP | claimed |
| US-20040026666-A1 | Imidazolium salts and their use of these ionic liquids as a solvent | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2004-02-12 | — | — | US | claimed |
| EP-1328518-A1 | IMIDAZOLIUM SALTS AND THE USE OF THESE IONIC LIQUIDS AS A SOLVENT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2003-07-23 | — | — | EP | claimed |
| EP-1201657-A1 | Imidazolium salts and the use of these ionic liquids as a solvent and as a catalyst | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2002-05-02 | — | — | EP | claimed |
| WO-2002034722-A1 | IMIDAZOLIUM SALTS AND THEIR USE OF THESE IONIC LIQUIDS AS A SOLVENT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2002-05-02 | — | — | WO | claimed |
| EP-0398358-B1 | Aluminum electroplating method | MITSUBISHI PETROCHEMICAL CO (JP) | 1994-03-09 | — | — | EP | claimed |
| EP-0404179-B1 | METHOD FOR PRODUCING AMBIENT TEMPERATURE MOLTEN SALT | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1993-09-01 | — | — | EP | claimed |
| US-5135825-A | Complexing, controlling temperature | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1992-08-04 | — | — | US | claimed |
| US-5041194-A | Using low melting mixture of aluminum halide and onium halide of nitrogen-containing compound | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1991-08-20 | — | — | US | claimed |
| EP-0404179-A1 | Method for producing ambient temperature molten salt | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1990-12-27 | — | — | EP | claimed |
| EP-0398358-A2 | Aluminum electroplating method | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1990-11-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617892-B2 | Application of the ring-opening of uretdiones at low temperature and ambient atmosphere | UQCRB, SCO2, UTS2R | CA1 696/4885CA2 1008/4885CTDSP1 460/4885 |
| US-12509547-B2 | Synthesis of linear polyoxazolidinones using uretdiones as diisocyanate component | BMP1, BMP4, PBRM1 | CA1 3664/4885CA2 3959/4885CTDSP1 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.